Indication: Miscellaneous Malignancies
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies
Sub-indication: Miscellaneous Malignancies
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Tizona Therapeutics, Inc.
Email for more information: MISC-NCIResearch@Nortonhealthcare.org